Browsing Tag
ARCHIMED
2 posts
ZimVie investors back $19 a share ARCHIMED deal, setting stage for major medtech shake-up
Find out how ZimVie’s shareholders approved a $19-per-share ARCHIMED acquisition and what it means for medtech investors and M&A sentiment.
NAMSA strengthens its MedTech leadership with WuXi AppTec deal
NAMSA, a global leader in MedTech testing, clinical research, and regulatory consulting, has announced its acquisition of WuXi…